ArticleOncotarget2015

The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway.

Emma M Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.